I would like to draw attention to an error in my recent Invited Commentary Hartung H-P. Neuromyelitis optica spectrum disorder: Therapeutic innovations and complex decision-making. Ann Neurol (s021);89:1084–1087.

The journal of publication of Reference 3 was incorrect and should have been:

Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder: a double-blind, randomized placebo-controlled phase 2/3 trial. Lancet 2019; 394: 1352–1363.

I regret and sincerely apologize for this error.